Memorial Sloan Kettering Cancer Center: Triple Negative Breast Neoplasms trials

The registry lists 11 Triple Negative Breast Neoplasms studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 5 are open to participants now and 3 have results posted.

Phase 1 3Phase 2 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast CancerRecruitingNCT07768436Phase 2
• A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast CancerRecruitingNCT06246968Phase 1
• A Study of SDX-7320 in Combination With Eribulin for People With Breast CancerRecruitingNCT05570253Phase 2
• A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast CancerRecruitingNCT04683679Phase 2
• Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of DiseaseRecruitingNCT03808337Phase 2
• A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following ChemotherapyCompletedNCT03542175Phase 1Results posted
• Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer PatientsCompletedNCT02730130Phase 2Results posted
• Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation TherapyActive, not recruitingNCT02422498Phase 2Results posted
• Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and LungActive, not recruitingNCT03808662Phase 2
• T-Cell Therapy for Advanced Breast CancerActive, not recruitingNCT02792114Phase 1
• Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast CancerActive, not recruitingNCT02750358Phase 2